No increased cancer risk after Viracept contamination
This article was originally published in Scrip
Executive Summary
Batches of Roche's HIV protease inhibitor Viracept (nelfinavir) contaminated with ethyl mesilate did not increase the risk of cancer developing in patients who took them, the European Medicines Agencyhas confirmed after reviewing toxicology studies. The European Commission suspended the product's marketing authorisation last June but the suspension was lifted in October when the problems at a Swiss manufacturing plant that led to the contamination had been resolved (Scrip Online, September 21st, 2007).